<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Epidermal growth factor receptor (EGFR) and Kras gene mutations are crucial for discriminating patients responsive to anti-EGFR drugs in <z:e sem="disease" ids="C0007131" disease_type="Neoplastic Process" abbrv="NSCLC">non-small cell lung cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NSCLC</z:e>) and <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>), respectively </plain></SENT>
<SENT sid="1" pm="."><plain>The majority of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NSCLCs</z:e> come to clinical attention at an advanced stage when surgery is no longer recommended and a considerable number of them are diagnosed by cytology only </plain></SENT>
<SENT sid="2" pm="."><plain>A large number of metastatic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRCs</z:e> are also diagnosed by imaging and minimally invasive techniques such as fine-needle <z:hpo ids='HP_0002835'>aspiration</z:hpo> biopsy </plain></SENT>
<SENT sid="3" pm="."><plain>Here, we report our experience in the mutation analysis of EGFR and Kras on cytological material obtained from superficial and deep lesions of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NSCLC</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Our series included 63 cytological specimens from primary or metastatic lesions of 42 NSCLCs and 21 CRCs </plain></SENT>
<SENT sid="5" pm="."><plain>The cytological material was adequate for the mutation analysis in 39/42 (93%) <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NSCLCs</z:e> and in 20/21(95%) <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRCs</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>EGFR and Kras mutations were found in 9 (23%) and 9 (23%) <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NSCLC</z:e> cases, respectively </plain></SENT>
<SENT sid="7" pm="."><plain>Kras mutations were found in 9/20 (45%) <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> specimens </plain></SENT>
<SENT sid="8" pm="."><plain>Histological samples from the <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumors</z:e> were available in 9/42 NSCLCs and in 17/21 CRCs </plain></SENT>
<SENT sid="9" pm="."><plain>The agreement of EGFR and Kras mutational status in cytological vs. histological samples was 100% for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NSCLC</z:e> and 88% for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>Our results suggest that standard cytology provides adequate material for the assessment of EGFR and Kras mutational status in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NSCLC</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients and could be specifically indicated in patients not eligible for surgery but candidate to anti-EGFR therapy </plain></SENT>
<SENT sid="11" pm="."><plain>Diagn </plain></SENT>
<SENT sid="12" pm="."><plain>Cytopathol </plain></SENT>
<SENT sid="13" pm="."><plain>2012 Â© 2012 Wiley Periodicals, Inc </plain></SENT>
</text></document>